Welcome to Dermbits! Watch short videos of KOLs answering your questions

thumbnail_dermbits-colorful.png

dermbits-colorful.png

Dermbits

DO, MPH

Any concern using topical JAK inhibitors in patients on dupilumab? 

JAK Inhibitors

When we're using agents for patients with moderate to severe atopic dermatitis, like dupliumob and even trailokinumob, the addition of a topical genus kinase inhibitor actually makes perfect sense. Now, the disclaimer is that those are off label uses on both sides. When we have dupiliumob, it really is on label, or for childocinumo, we wouldn't necessarily, from the package insert, use this. But I think most of us in clinical practice feel like there are different mechanisms of action and there is collaborative impact on downregulation of very important th two cytokines, like interleukin four and interleukin 13. And I think that we get a reestablishment of the skin barrier not only from utilizing the systemic biologic therapy, but also the improvements that we get from using a localized topical therapy. And we avoid some of the consequences that we would get from using concurrently a topical corticosteroids, as was done in the clinical trials. For instance, dupiliumab.

Any concern using topical JAK inhibitors in patients on dupilumab?

Related CME